Comparative Pharmacology
Head-to-head clinical analysis: LODINE XL versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE XL versus NAPROXEN SODIUM.
LODINE XL vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
400 mg or 600 mg orally once daily.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID